Industrial Technology Research Institute

Shuen-Hsiang Chou

Chih-Peng Liu

Maggie J M Lu

Min-Ying Lin

Ming-Cheng Wei

Tsan-Lin Hu

Chia-Mu Tu

Maggie Lu

Yi-Ju Ko

Felice Cheng

Ya-Chin Lo

Hsiang-Wen Tseng

Yu-Wen Lo

Shih-Ta Chen

Po-Hung Lai

Chia-Wen Huang

Disclosed is an intralymphatic delivery method for treating lymphatic cancer using hyaluronan nanoparticles. These nanoparticles include a hyaluronic acid derivative and a platinum compound. The hyaluronan derivative includes hyaluronic acid, modified histidine and optionally one or more of a polymer or a C-Calkyl. The hyaluronic acid derivative may include linking group(s) that connect the polymer or the C-Calkyl to the hyaluronic acid. The platinum compound includes dichloro(1,2-diaminocyclohexane) platinum (DACHPt), cisplatin and oxaliplatin. This intralymphatic delivery method offers significant advantages for the use of platinum medicines in treating lymphatic cancer.

Intralymphatic delivery of hyaluronan nanoparticle for cancer metastasis

The disclosure provides a recipe for in-situ gel, formed by dissolving at least one polymer and at least one gel prevention agent in a polar solvent to form a solution and placing the solution in a condition for in-situ forming gels. The disclosure also provides an implant and a drug delivery system formed by the recipe.

Recipe for in-situ gel, and implant, drug delivery system formed thereby

The disclosure provides a pharmaceutical composition. The pharmaceutical composition includes a chitosan with palmitoyl groups and an active agent. According to another embodiment, the pharmaceutical composition can further include a gelling accelerating agent. According to an embodiment of the disclosure, the active agent of the disclosure can be administered in the form of a nano-drug, liposome, micelle, or microparticle.

Pharmaceutical composition

Growing community of inventors

Zhunan, Taiwan

Shuen-Hsiang Chou